2026年梯瓦制药历年年报/社会责任报告/ESG报告合集（共32套打包）

1、UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON,D.C.20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended S。

2、Teva Pharmaceutical Industries Ltd.November 5,20252|This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995,which are based on。

3、 Corrected Transcript 1-877-FACTSET Total Pages:19 Copyright 2001-2025 FactSet CallStreet,LLC 05-Nov-2025 Teva Pharmaceutical Industries Ltd.(TEVA)Q3 2025 Earnings Call Teva Pharmaceutical Industries。

4、UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,D.C.20549 FORM 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended 。

5、 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON,D.C.20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended 。

6、Teva Pharmaceutical Industries Ltd.May 7,20252|This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995,which are based on mana。

7、 Corrected Transcript 1-877-FACTSET Total Pages:17 Copyright 2001-2025 FactSet CallStreet,LLC 07-May-2025 Teva Pharmaceutical Industries Ltd.(TEVA)Q1 2025 Earnings Call Teva Pharmaceutical Industries。

8、UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,D.C.20549 FORM 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended 。

9、Table of Contents UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 FORM 10-K (Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fi。

10、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THESECURITIES EXCHANGE ACT OF 1934For the fiscal year ended Decem。

11、Table of Contents UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 FORM 10-K (Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fi。

12、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THESECURITIES EXCHANGE ACT OF 1934For the fiscal year ended Decem。

13、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THESECURITIES EXCHANGE ACT OF 1934For the fiscal year ended Decem。

14、Table of Contents UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 FORM 10-K (Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fi。

15、Table of Contents UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIES EXCHANGE ACT OF 1934OR ANNUAL REP。

16、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 20-FREGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIESEXCHANGE ACT OF 1934ORANNUAL REPORT PURSUANT TO SECTI。

17、Teva Pharmaceutical Industries LimitedContentsTeva at a Glance 4President and Chief Executive Officers Letter to Shareholders 6Financial Highlights 10Business Overview 12Global Reach 16Leadership 18S。

18、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 20-FREGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIESEXCHANGE ACT OF 1934ORANNUAL REPORT PURSUANT TO SECTI。

19、Table of Contents UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIES EXCHANGE ACT OF 1934OR xANNUAL RE。

20、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 20-FREGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIESEXCHANGE ACT OF 1934ORANNUAL REPORT PURSUANT TO SECTI。

21、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 20-FREGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIESEXCHANGE ACT OF 1934ORANNUAL REPORT PURSUANT TO SECTI。

22、v UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON,D.C.20549 FORM 20-F?REGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIES EXCHANGE ACT OF 1934 OR ANNUAL REPORT PURSUANT。

23、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 20-FREGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIESEXCHANGE ACT OF 1934ORANNUAL REPORT PURSUANT TO SECTI。

24、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 20-FREGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIES EXCHANGE ACT OF1934ORANNUAL REPORT PURSUANT TO SECTI。

25、Sustainability at our HeartHealthy Future encompasses our approach to promoting healthy people,a healthy planet and ahealthy business.We are proud to share our 2024 Healthy Future Report,whichsets ou。

26、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 20-FREGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIES EXCHANGE ACTOF 1934OrANNUAL REPORT PURSUANT TO SECTI。

27、Teva 2014 Global Citizenship ReportInnovating for Better HealthABOUT TEVATeva at a glanceMessage from our President and CEO:Erez VigodmanCitizenship at Teva2014 citizenship highlightsA European persp。

28、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 20-FREGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIESEXCHANGE ACT OF 1934OrANNUAL REPORT PURSUANT TO SECTI。

29、1Corporate SocialMeeting Our Patients NeedsResponsibility Report2Teva CSR CEO LetterA Letter From Erez Vigodman,Tevas President&CEOThis approach is not new to Teva:for over 113 years,we have been。

30、UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON,D.C.20549 FORM 20-F Or For the fiscal year ended December 31,2004 Or For the transition period from to Commission File number:0-16174 TEVA 。

31、Meeting Patient Needs2012 Corporate Social Responsibility Reporta A 6 ,About TevaOur patientsOur employeesOur communityOur environmental commitmenta A 6 ,About TevaOur patientsOur employeesOur commun。

32、UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON,D.C.20549 FORM 20-F?REGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIES EXCHANGE ACT OF 1934 Or ANNUAL REPORT PURSUANT T。